(Q37728984)

English

Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer

scientific article published on 11 April 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Christopher S Bryant

1

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Sanjeev Kumar

2

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Whitney Spannuth

3

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Jay P Shah

4

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Adnan R Munkarah

5

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Gunter Deppe

6

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Ronald D Alvarez

7

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Robert T Morris

8

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

11 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Archives of Gynecology and Obstetrics

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

283

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

361-367

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

https://scigraph.springernature.com/pub.10.1007/s00404-010-1462-9

0 references

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Diagnosis and management of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Weekly topotecan in the management of ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Topotecan: weighing in when there are many options

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Optimal sequencing in the treatment of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwe

1 reference

https://api.crossref.org/works/10.1007%2FS00404-010-1462-9

21 January 2018

Identifiers

10.1007/S00404-010-1462-9

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37728984&oldid=2151735434"